Miah M A, Ahmed S S, Chowdhury S A, Begum F, Rahman S H
Department of Dermatology and Venereology, Mymensingh Medical College & Hospital, Mymensingh, Bangladesh.
Mymensingh Med J. 2008 Jul;17(2 Suppl):S1-5.
This prospective study on Fixed Drug Eruption (FDE) was carried out between January 2003 to December 2006 in Dermatology department of Mymensingh Medical College Hospital & private chambers. This study was carried out with an objective to see the specific site of involvement and other clinical parameters in FDE due to cotrimoxazole. In each case, a detailed history was taken and a thorough physical examination was done by at least one dermatologist. Patients with suspected FDE, who had consented, were included in the study. Oral re-challenge test was done in each case after written or verbal consent of the patient or legal guardian. For oral re-challenge, usually half of the usual therapeutic dose of the suspected drug (s) was given first and reactions were observed and if no reaction, then full therapeutic dose was given and then again reactions were observed. In case of no reaction to one drug, the next drug was tested after 2 to 7 days. Age & sex distribution, number of attacks of FDE, number of lesions, distribution of sites of involvement were determined in each case of FDE. All informations were recorded in pre-tested data sheet. Among 93 patients of suspected FDE, 61 patients were confirmed as FDE with identified causes, of which 36 cases were due to cotrimoxazole (59.02%). Age range of patients was from 5 years to 65 years with mean of 24.92 years. Male was predominantly affected (M:F=6.2:1). In 50% cases presenting attack was the 2nd attack. Rest 50% had 3 to more than 10 attacks. Number of lesions was: 2-5 lesions in 50%, solitary lesion in 16.67%, 6-10 lesions in 13.89% and more than 10 lesions in 19.44% cases. Sites of involvement in cases of FDE due to cotrimoxazole (n=36) were as follows: lips 58.33%, genitalia 33.33%, oral 13.89%, trunk 38.89%, limbs 55.56%, hands 16.67%, feet 19.44%, face 19.44% and conjunctiva 2.78%.
这项关于固定性药疹(FDE)的前瞻性研究于2003年1月至2006年12月在迈门辛希医学院医院皮肤科及私人诊室开展。本研究旨在观察由复方新诺明引起的固定性药疹的具体受累部位及其他临床参数。对每例患者均详细询问病史,并至少由一名皮肤科医生进行全面体格检查。经同意的疑似固定性药疹患者被纳入研究。在患者或其法定监护人书面或口头同意后,对每例患者进行口服再激发试验。进行口服再激发试验时,通常先给予疑似药物常用治疗剂量的一半,观察反应,若没有反应,则给予全治疗剂量,然后再次观察反应。若对一种药物无反应,则在2至7天后测试下一种药物。确定每例固定性药疹患者的年龄和性别分布、固定性药疹发作次数、皮损数量、受累部位分布情况。所有信息均记录在预先测试的数据表中。在93例疑似固定性药疹患者中,61例被确诊为固定性药疹且病因明确,其中36例由复方新诺明引起(59.02%)。患者年龄范围为5岁至65岁,平均年龄24.92岁。男性受累为主(男∶女 = 6.2∶1)。50%的病例此次发作是第2次发作。其余50%有3次至10次以上发作。皮损数量情况为:50%的病例有2至5个皮损,16.